ABSTRACT
INTRODUCTION
Infants with birth size small for gestational age (SGA) can represent up to 10% of all live births each year, depending on the definition used [1] . While the majority of children born SGA achieve appropriate catch-up growth by the age of 2-3 years, approximately one in ten does not, and these children are at increased risk of childhood and adult short stature [2, 3] .
Therefore, current guidelines recommend early intervention [in the form of treatment with recombinant human growth hormone (rhGH), somatropin] for short children born SGA who still show severe growth retardation by 2-4 years of age [4] . In addition, epidemiological evidence suggests that children born SGA may also be at an increased risk of insulin resistance and type 2 diabetes in later life [5, 6] and there is also an association between low birth weight and later health problems, such as heart disease and stroke [4] .
The efficacy and safety of GH therapy for children born SGA has been demonstrated in several studies [7] [8] [9] [10] . However, given that GH therapy can induce transient insulin resistance in children [11] , concerns exist over its diabetogenic potential in individuals inherently predisposed to metabolic abnormalities, such as children born SGA. Currently, there is a paucity of long-term data on the use of rhGH therapy in short children born SGA, as well as its impact on diabetes. This ongoing, long-term, phase IV multicentre study with rhGH (Omnitrope Ò , Sandoz GmbH, Kundl, Austria) is the largest prospective clinical study of GH therapy in SGA patients conducted to date. The safety and efficacy of rhGH therapy will be thoroughly evaluated, especially in terms of its diabetogenic potential and its ability to stimulate growth.
Here we report data from the first interim analysis of patients who have completed 1 year of treatment. Patients could voluntarily withdraw from the study at any time.
METHODS

Study Design and Patients
Study Treatment
Patients were treated with rhGH 0.035 mg/kg/ day by subcutaneous injection in the evening.
The investigator trained the patients (or their legal guardians) to administer the study drug as prescribed. Doses had to be adjusted at each study visit within defined limits. Concomitant medications could be given at the investigator's discretion.
Study Objectives
The primary objective is to evaluate the longterm effect of rhGH treatment on the development of diabetes mellitus in short children born SGA. In this paper we present data after 1-year of follow-up.
Secondary objectives include an evaluation of efficacy through changes in height parameters; measurement of rhGH-induced serum markers IGF-I and insulin-like growth factor-binding protein 3 (IGFBP-3); incidence and severity of adverse events (AEs) and detection of anti-rhGH antibodies during treatment.
Timing of Assessments
Height was measured in cm and HV calculated.
HSDS and HVSDS (based on country-specific reference tables) were assessed at baseline and at 3-month intervals throughout the first year. To determine bone age, X-rays of the left hand and wrist were obtained at baseline and once-yearly thereafter.
IGF-I and IGFBP-3 were measured by a central laboratory at screening and at 3, 6, 9 and 12 months thereafter. IGF-I and IGFBP-3 serum levels were categorised as low (\-2 SD), normal, or high ([?2 SD), compared with the normal ranges, and serum level changes from baseline to Year 1 were analysed.
Fasting plasma glucose, 2-h OGTT, HbA 1c and insulin levels were measured at baseline, 6 months, 12 months and annually thereafter.
Homeostatic model assessment (HOMA) score (marker of insulin resistance) and the quantitative insulin sensitivity check index (QUICKI) were calculated as previously described [12] [13] [14] .
All AEs were recorded at each visit and their incidence is reported using the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, version 14.0 or higher [15] . Like all patients that are treated within this study, patients classed as ''non-responders'' are also offered the option to participate in a 10-year follow-up safety study (EP00-402; NCT01491854). During this 10-year follow-up, all patients included will be analysed for safety, with particular emphasis on the development of diabetes after the end of rhGH therapy. 
Additional Safety Assessments
Statistical Analyses and Patient Populations
The current analysis includes data from baseline up to the 1-year visit. Further analyses are planned for 2013 (2 year-visit) and 2021 (end of treatment). All analyses were performed using SAS Table 1 . Slightly more patients were males (53.2%) than females, mean age on admission to the study was 
RESULTS
Patients
Pubertal Status
Only pre-pubertal children were enrolled in the study (Table 1) 
Additional Safety Assessments
A total of 649 treatment-emergent AEs were reported in 192 children (69.3%); most (98.7%)
were mild-to-moderate in intensity and the majority (96.5%) were judged to be unrelated to study treatment. The most frequently occurring AEs (by MedDRA preferred term) were nasopharyngitis (n = 53, 19.1%), pharyngitis (n = 51, 18.4%), upper respiratory tract infections (n = 25, 9%) and bronchitis (n = 23, 8.3%) ( Table 3) . AEs with a suspected relationship to study drug were rare; the most frequently reported were hypothyroidism (7 patients, 2.5%) and headache (3 patients, 1.1%).
Serious AEs were reported in 19 patients (6.9%), with only one suspected to be treatment-related (severe headache). No malignancies have been observed in the study to date, no patients have died during the first year of treatment and only one patient discontinued from the study due to a nonserious AE (crying, aggressiveness and refusing to take injections), which was considered unrelated to the study drug. There were no clinically significant findings in haematological parameters, blood chemistry, urinalysis, or vital signs.
Efficacy Assessments (Secondary Endpoints)
Body height increased steadily throughout the treatment period; mean changes from baseline were slightly greater in girls (9.29 cm) than in boys (8.90 cm). Likewise, mean HSDS showed a continuous increase and improved by 0.81 overall (p\0.0001) (Fig. 2) . While this reflects a net improvement of height, the values achieved indicate that the mean height of the study population was still shorter than average after 1 year of treatment.
Mean HV increased markedly during the first 3 months of treatment (10.72 cm/year compared with 4.25 cm/year at baseline; p\0.0001) and then decreased slightly but remained higher than at baseline (8.99 cm/year after 1 year; p\0.0001) (Fig. 3a) . There was no apparent difference between boys and girls in terms of (Fig. 3b) . A small number of children (13/278, 4.7%)
did not respond adequately to treatment after the first year (HVSDS \1) and were withdrawn from treatment.
IGF-I and IGFBP-3
IGF-I and IGFBP-3 were measured as surrogate indicators of treatment efficacy. Mean IGF-I SDS showed a steady increase from baseline (-1.08)
to Year 1 (?0.72) (p\0.0001) (Fig. 4a) . Shifts in IGF-I serum level categories indicated that at baseline most patients had normal (n = 208; 77.3%) or low (\-2 SD) IGF-I levels (n = 44; 16.4%). At 1 year, this distribution shifted, so that only two patients had low levels and the majority had normal (n = 202; 75.1%) or high (n = 40; 14.9%) IGF-I levels.
Mean IGFBP-3 SDS was ?0.11 at baseline, increasing to ?0.52 at Year 1 (p\0.0001) (Fig. 4b) . Shifts in IGFBP-3 serum level categories showed that the majority of patients (n = 247; 91.8%) had normal IGFBP-3 levels at baseline. At Year 1, this distribution was essentially unchanged, with 232 patients abnormality of fasting or post-prandial glucose [16] . GH treatment, with its insulin antagonistic action, could potentially increase the risk of type 2 diabetes in this patient group [11] .
The main objective of the present study is to evaluate the effect of rhGH treatment on the development of diabetes in short children born SGA. In this first interim analysis, no patients developed diabetes during the first year of treatment. Glucose levels (fasting plasma glucose), glucose tolerance (OGTT) and HbA 1c remained stable over the first year of treatment, while fasting insulin increased slightly. These findings are consistent with the concept that, while GH treatment may increase insulin resistance in children born SGA, there is a compensatory hyperinsulinaemia that maintains normal glucose regulation during treatment [17] .
These 1-year interim data are also consistent with data from a study of glucose tolerance and insulin sensitivity during GH treatment of 84 children born SGA, which reported that while a reduction in insulin sensitivity was observed, glucose tolerance remained normal [10] . In addition, other recent studies in children born SGA reported that any rhGH-induced changes in insulin levels reverted to normal upon treatment discontinuation, while fasting blood glucose remained within normal limits during a 2-year treatment period [18] . The incidence of anti-rhGH antibodies during the first year of treatment was low. This is consistent with findings from other longer-term studies examining the efficacy and safety of rhGH in children with GH deficiency, which have also reported low levels of anti-rhGH antibodies after 4-7 years of treatment [19, 20] . The incidence of treatment-related hypothyroidism (2.5%) and headache (1.1%) reported in this study was comparable to other clinical trials. Moreover, it is generally recognised that rhGH therapy has a good safety profile in children born SGA [1] .
The increase in growth velocity and height gain during the first year of GH treatment in the present study was excellent and compares favourably with data reported in several other studies of SGA children treated with various rhGH products [7] [8] [9] [10] 16 ]. However, consensus guidelines consider a positive growth response within the first year of GH treatment as a change in HVSDS of more than ?0.5 [4] . In the present study, this was achieved in all patients classified as responders, since the study protocol applied a stricter definition, i.e. HVSDS had to be at least ?1
after the first year of treatment for patients to be eligible to continue with therapy.
An obvious limitation of the study is the lack of an (untreated) control group. Another potential limitation is that most patients were older than 4 years at initiation of rhGH therapy. However, the statistically significant treatment benefits that were observed in the majority of patients across all height parameters indicate that this is a GH-responsive population. The few non-responsive patients were withdrawn from the study at the 1-year visit, as stipulated by the approved study protocol.
CONCLUSIONS
The results of this first interim analysis show that short children born SGA can be effectively 
